ArticleIranian journal of biotechnology2025
Evaluation of the Safety of A Novel Anti-HER2 Immunotoxin Containing Modified Fragment of
Article in Iranian journal of biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Human epidermal growth factor-2 (HER-2) receptors are overexpressed in some malignancies like breast cancer. Previously, we constructed a novel anti-HER immunotoxin, scFv-PE35KDEL, containing modified fragments of Objectives: The objective of this research was to express and purify the recombinant scFv-PE35KDEL protein and remove its endotoxin content, as well as to evaluate its toxicity profile by determining the LD Materials and Methods: After expression and purification of scFv-PE35KDEL, BALB/c mice were intraperitoneally administered single doses of 250, 500, 1000, and 2000 µg.kg Results: All mice died after a single dose of 2000 µg.kg Conclusion: These findings revealed that the LD50 of scFv-PE35KDEL is in the range of 1000-2000 µg.mg
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.